CMS Grants New Procedure Code for the MISHA® Knee System
An FDA breakthrough treatment for medial knee osteoarthritis patients not ready for a knee replacement
The MISHA Knee System is the result of over a decade of clinical research and development and is the first implantable shock absorber for the treatment of medial knee osteoarthritis (OA). This breakthrough treatment is indicated for patients who failed to find relief from previous treatments, and are unwilling to undergo or ineligible for total knee replacement due to age or absence of advanced OA.1
Demonstrated to provide rapid and significant improvement in pain and function, the MISHA Knee System is a revolutionary knee solution that preserves the joint and has the potential to delay arthroplasty.2-3
Learn more at https://moximed.com/misha/
Effective January 1, 2025 the Centers for Medicare & Medicaid Services (CMS) has established a new Healthcare Common Procedure Coding System (HCPCS) C-Code for the MISHA Knee System and assigned it to an Ambulatory Payment Classification (APC).
HCPCS C-Code C8003, which is assigned to APC 5116, allows hospital outpatient departments (HOPD) and ambulatory surgery centers (ASC) to report the implantation of the MISHA Knee System for Medicare patients.
With experienced med-tech leadership and strong investor support, Moximed is poised to elevate the standard of care and quality of life for millions of pre-arthroplasty knee OA sufferers hindered by arthritic knee pain and function loss.
If you are interested in speaking with a Moximed Territory Manager to learn more, please complete the contact form online here: https://moximed.com/contact-us/
REFERENCES: 1. MISHA Knee System Instructions for Use (IFU). LBL103253. 2. Diduch DR, Crawford DC, Ranawat AS, Victor J, Flanigan DC. Implantable Shock Absorber Provides Superior Pain Relief and Functional Improvement Compared With High Tibial Osteotomy in Patients with Mild-to-Moderate Medial Knee Osteoarthritis: A 2-Year Report. CARTILAGE. 2023;0(0). doi:10.1177/19476035231157335. 3. Gomoll, Andreas H et al. “An implantable shock absorber yields an 85% survival-from-arthroplasty rate through 5 years in working-age patients with medial compartment knee osteoarthritis.” Knee surgery, sports traumatology, arthroscopy : official journal of the ESSKA vol. 31,8 (2023): 3307-3315. doi:10.1007/s00167-023-07373-4.